Optimind Pharma Corp.
OMND
CNSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.69% | 8.18% | 36.60% | -6.26% | -19.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.69% | 8.18% | 36.60% | -6.26% | -19.90% |
| Cost of Revenue | 35.92% | 9.60% | -7.28% | -25.31% | -61.57% |
| Gross Profit | 3.19% | 7.35% | 82.20% | 14.29% | 87.68% |
| SG&A Expenses | -69.20% | -76.91% | -62.83% | -60.51% | -39.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.68% | -70.25% | -58.82% | -64.21% | -52.50% |
| Operating Income | 85.84% | 91.93% | 78.42% | 73.66% | 58.44% |
| Income Before Tax | 92.94% | 95.49% | 89.51% | 84.95% | 66.25% |
| Income Tax Expenses | -- | -- | -- | -- | -51.16% |
| Earnings from Continuing Operations | 92.88% | 95.45% | 89.42% | 84.85% | 66.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.88% | 95.45% | 89.42% | 84.85% | 66.51% |
| EBIT | 85.84% | 91.93% | 78.42% | 73.66% | 58.44% |
| EBITDA | -- | -- | -- | -- | 82.12% |
| EPS Basic | 92.19% | 94.37% | 88.61% | 85.44% | 68.47% |
| Normalized Basic EPS | 90.91% | 96.43% | 88.24% | 83.67% | 47.62% |
| EPS Diluted | 92.19% | 94.37% | 88.61% | 85.44% | 68.47% |
| Normalized Diluted EPS | 90.91% | 96.43% | 88.24% | 83.67% | 47.62% |
| Average Basic Shares Outstanding | -4.31% | -0.15% | 3.98% | 11.99% | 12.33% |
| Average Diluted Shares Outstanding | -4.31% | -0.15% | 3.98% | 11.99% | 12.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |